北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker
作者: Zeng, G; Aldridge, ME; Wang, Y; Pantuck, AJ; Wang, AY; Liu, YX; Han, Y; Yuan, YH; Robbins, PF; Dubinett, SM; DeKernion, JB; Belldegrun, AS
关键词: SEREX ; tumor antigen ; immunotherapy ; tumor biomarker ; cancer vaccine
刊名: INTERNATIONAL JOURNAL OF CANCER
发表日期: 2005-03-20
DOI: 10.1002/ijc.20716
卷: 114, 期:2, 页:268-273
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: HUMAN TUMOR-ANTIGENS ; IMMUNE-RESPONSES ; ANTIBODY ; PROTEIN ; IMMUNOTHERAPY ; EXPRESSION ; IDENTIFICATION ; TARGETS ; LAGE-1 ; PANEL
英文摘要:

Monitoring the spontaneous antibody (Ab) response against a panel of relevant tumor-associated antigens (TAA) in cancer patients may provide useful information regarding the clinical status of cancer. However, current Ab detection approaches require the purification of recombinant proteins, which is often difficult to achieve. In order to bypass the purification of recombinant proteins, we identified a dominant B-cell epitope from a shared tumor antigen NY-ESO-1. A synthetic peptide of the epitope, ESO:1-40, was as sensitive as the recombinant protein for detecting Ab against NY-ESO-1 in most patients. NY-ESO-1 specific Ab present in the sera of patients with melanoma, prostate cancer, nonsmall cell lung cancer, esophageal cancer, gastric cancer and hepatocellular carcinoma reacted with the dominant peptide at a similar frequency as the recombinant protein. To our knowledge, ESO: 1-40 is the first peptide epitope recognized by sera from a wide spectrum of cancer patients but not healthy donors. This simple and straightforward approach may allow the investigation of the clinical significance of spontaneous Ab responses against multiple TAA and their correlation with the clinical course of malignant diseases in the future. (C) 2004 Wiley-Liss, Inc.

语种: 英语
WOS记录号: WOS:000226734200016
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65461
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Univ Calif Los Angeles, David Geffen sCh Med, Hlth Sci Ctr, Dept Urol, Los Angeles, CA 90095 USA
2.Univ Calif Los Angeles, David Geffen sCh Med, Hlth Sci Ctr, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
3.Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA
4.Peking Univ, Med Ctr, Beijing Canc Hosp, Beijing 100871, Peoples R China
5.Natl Canc Inst, Surg Branch, Bethesda, MD USA

Recommended Citation:
Zeng, G,Aldridge, ME,Wang, Y,et al. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker[J]. INTERNATIONAL JOURNAL OF CANCER,2005,114(2):268-273.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zeng, G]'s Articles
[Aldridge, ME]'s Articles
[Wang, Y]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zeng, G]‘s Articles
[Aldridge, ME]‘s Articles
[Wang, Y]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace